{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:09:44Z","timestamp":1761588584450,"version":"build-2065373602"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.intimp.2023.110485","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T07:25:39Z","timestamp":1686900339000},"page":"110485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19"],"prefix":"10.1016","volume":"121","author":[{"given":"Dan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chujiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-9078","authenticated-orcid":false,"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10229","key":"10.1016\/j.intimp.2023.110485_b0005","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","article-title":"Clinical course and mortality risk of severe COVID-19","volume":"395","author":"Weiss","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.intimp.2023.110485_b0010","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1871526514666140713152858","article-title":"Sensitivity of SARS\/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans","volume":"14","author":"Strayer","year":"2014","journal-title":"Infect. Disord. Drug Targets"},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110485_b0025","first-page":"E012","article-title":"Pharmacotherapeutics for the New Coronavirus Pneumonia","volume":"43","author":"Du","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.intimp.2023.110485_b0030","doi-asserted-by":"crossref","first-page":"17554","DOI":"10.1038\/srep17554","article-title":"Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2023.110485_b0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/095632020501600103","article-title":"Current status of anti-SARS agents","volume":"16","author":"Shigeta","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"issue":"24","key":"10.1016\/j.intimp.2023.110485_b0045","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study","volume":"290","author":"Loutfy","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.intimp.2023.110485_b0050","unstructured":"World Health Organization, 2022. https:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html."},{"key":"10.1016\/j.intimp.2023.110485_b0055","unstructured":"Johns Hopkins University & Medicine, 2022. https:\/\/coronavirus.jhu.edu\/map.html."},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/jmm.0.000565","article-title":"A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective","volume":"66","author":"Rabaan","year":"2017","journal-title":"J. Med. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vbz.2017.2191","article-title":"What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans?","volume":"19","author":"Dawson","year":"2019","journal-title":"A Systematic Literature Review, Vector Borne Zoonotic Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2023.110485_b0075","doi-asserted-by":"crossref","unstructured":"A. Assiri, A. McGeer, T.M. Perl, C.S. Price, A.A. Al Rabeeah, D.A. Cummings, Z.N. Alabdullatif, M. Assad, A. Almulhim, H. Makhdoom, H. Madani, R. Alhakeem, J.A. Al-Tawfiq, M. Cotten, S.J. Watson, P. Kellam, A.I. Zumla, Z.A. Memish, K.M.-C.I. Team, Hospital outbreak of Middle East respiratory syndrome coronavirus, N Engl J Med. 369(5) (2013) 407-16, 10.1056\/NEJMoa1306742.","DOI":"10.1056\/NEJMoa1306742"},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13054-016-1303-8","article-title":"Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients","volume":"20","author":"Almekhlafi","year":"2016","journal-title":"Crit. Care"},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0085","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","article-title":"Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)","volume":"72","author":"Kim","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.110485_b0090","doi-asserted-by":"crossref","unstructured":"T. Sumi, K. Harada, Immune response to SARS-CoV-2 in severe disease and long COVID-19, iScience. 25(8) (2022) 104723, 10.1016\/j.isci.2022.104723.","DOI":"10.1016\/j.isci.2022.104723"},{"key":"10.1016\/j.intimp.2023.110485_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101300","article-title":"Global virus outbreaks: Interferons as 1st responders","volume":"43","author":"Wang","year":"2019","journal-title":"Semin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jit504","article-title":"Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis","volume":"209","author":"Zhou","year":"2014","journal-title":"J Infect Dis"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2023.110485_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.antiviral.2006.05.019","article-title":"Coronaviruses and their therapy","volume":"71","author":"Haagmans","year":"2006","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110485_b0110","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1128\/JVI.03607-14","article-title":"High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus","volume":"89","author":"Scheuplein","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2023.110485_b0115","doi-asserted-by":"crossref","unstructured":"Y. Arai, I. Yamanaka, T. Okamoto, A. Isobe, N. Nakai, N. Kamimura, T. Suzuki, T. Daidoji, T. Ono, T. Nakaya, K. Matsumoto, D. Okuzaki, Y. Watanabe, Stimulation of interferon-beta responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists, iScience. 26(1) (2023) 105742, 10.1016\/j.isci.2022.105742.","DOI":"10.1016\/j.isci.2022.105742"},{"key":"10.1016\/j.intimp.2023.110485_b0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.immunol.25.022106.141706","article-title":"The Immunobiology of SARS*","volume":"25","author":"Chen","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.110485_b0125","article-title":"Cell-type specific distribution and activation of type I IFN pathway molecules at the placental maternal-fetal interface in response to COVID-19 infection","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0130","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.110485_b0135","doi-asserted-by":"crossref","unstructured":"A. Banerjee, N. El-Sayes, P. Budylowski, R.A. Jacob, D. Richard, H. Maan, J.A. Aguiar, W.L. Demian, K. Baid, M.R. D'Agostino, J.C. Ang, T. Murdza, B.J. Tremblay, S. Afkhami, M. Karimzadeh, A.T. Irving, L. Yip, M. Ostrowski, J.A. Hirota, R. Kozak, T.D. Capellini, M.S. Miller, B. Wang, S. Mubareka, A.J. McGeer, A.G. McArthur, A.C. Doxey, K. Mossman, Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses, iScience. 24(5) (2021) 102477, 10.1016\/j.isci.2021.102477.","DOI":"10.1016\/j.isci.2021.102477"},{"key":"10.1016\/j.intimp.2023.110485_b0140","doi-asserted-by":"crossref","unstructured":"B. Diamond, B.T. Volpe, S. VanPatten, Y. Al Abed, SARS-CoV-2 and interferon blockade, Mol Med. 26(1) (2020) 103, 10.1186\/s10020-020-00231-w.","DOI":"10.1186\/s10020-020-00231-w"},{"issue":"2","key":"10.1016\/j.intimp.2023.110485_b0145","doi-asserted-by":"crossref","first-page":"e88716","DOI":"10.1371\/journal.pone.0088716","article-title":"Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?","volume":"9","author":"Faure","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0150","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/JVI.03496-12","article-title":"Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus","volume":"87","author":"Zielecki","year":"2013","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/157489106778777637","article-title":"SARS coronavirus anti-infectives","volume":"1","author":"Tong","year":"2006","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2023.110485_b0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cytogfr.2008.01.001","article-title":"Interferon and cytokine responses to SARS-coronavirus infection","volume":"19","author":"Thiel","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11262-010-0544-x","article-title":"SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism","volume":"42","author":"Lu","year":"2011","journal-title":"Virus Genes"},{"issue":"12","key":"10.1016\/j.intimp.2023.110485_b0170","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13238-013-3096-8","article-title":"The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0175","doi-asserted-by":"crossref","first-page":"e01174","DOI":"10.1128\/mBio.01174-14","article-title":"Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses","volume":"5","author":"Menachery","year":"2014","journal-title":"MBio"},{"issue":"12","key":"10.1016\/j.intimp.2023.110485_b0180","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A review of treatment modalities for Middle East Respiratory Syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.intimp.2023.110485_b0185","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110485_b0190","doi-asserted-by":"crossref","unstructured":"H. Zhu, F. Zheng, L. Li, Y. Jin, Y. Luo, Z. Li, J. Zeng, L. Tang, Z. Li, N. Xia, P. Liu, D. Han, Y. Shan, X. Zhu, S. Liu, R. Xie, Y. Chen, W. Liu, L. Liu, X. Xu, J. Wang, H. Yang, X. Shen, X. Jin, F. Cheng, A Chinese host genetic study discovered IFNs and causality of laboratory traits on COVID-19 severity, iScience. 24(10) (2021) 103186, 10.1016\/j.isci.2021.103186.","DOI":"10.1016\/j.isci.2021.103186"},{"key":"10.1016\/j.intimp.2023.110485_b0195","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.aivir.2016.08.006","article-title":"Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response","volume":"96","author":"Kindler","year":"2016","journal-title":"Adv. Virus Res."},{"issue":"9380","key":"10.1016\/j.intimp.2023.110485_b0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2023.110485_b0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.110485_b0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-beta 1a and SARS coronavirus replication","volume":"10","author":"Hensley","year":"2004","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2004.08.011","article-title":"Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)","volume":"329","author":"Sainz","year":"2004","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.intimp.2023.110485_b0220","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","article-title":"Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines","volume":"326","author":"Morgenstern","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.intimp.2023.110485_b0225","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/382597","article-title":"Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha","volume":"189","author":"Stroher","year":"2004","journal-title":"J Infect Dis"},{"issue":"11\u201312","key":"10.1016\/j.intimp.2023.110485_b0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/00365540410021144","article-title":"In vitro inhibition of SARS virus replication by human interferons","volume":"36","author":"Dahl","year":"2004","journal-title":"Scand. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcv.2003.11.013","article-title":"The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein","volume":"30","author":"Spiegel","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0240","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"2\u20133","key":"10.1016\/j.intimp.2023.110485_b0245","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2005.09.014","article-title":"Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide","volume":"118","author":"Bao","year":"2006","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110485_b0250","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1086\/425357","article-title":"Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing","volume":"39","author":"Chen","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.110485_b0255","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/135965350400900618","article-title":"Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons","volume":"9","author":"Scagnolari","year":"2004","journal-title":"Antivir. Ther."},{"issue":"Pt 3","key":"10.1016\/j.intimp.2023.110485_b0260","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/vir.0.061911-0","article-title":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays","volume":"95","author":"Hart","year":"2014","journal-title":"J. Gen. Virol."},{"issue":"Pt 8","key":"10.1016\/j.intimp.2023.110485_b0265","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.intimp.2023.110485_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104860","article-title":"The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium","volume":"180","author":"Jeon","year":"2020","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.intimp.2023.110485_b0275","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.110485_b0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2018.05.007","article-title":"Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model","volume":"155","author":"Li","year":"2018","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.110485_b0285","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2023.110485_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res."},{"issue":"23","key":"10.1016\/j.intimp.2023.110485_b0295","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01410-20","article-title":"Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110485_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/v12060628","article-title":"Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)","volume":"12","author":"Yuan","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1001","article-title":"Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques","volume":"10","author":"Haagmans","year":"2004","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2023.110485_b0310","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment With Lopinavir\/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"issue":"21","key":"10.1016\/j.intimp.2023.110485_b0315","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1128\/JVI.00747-06","article-title":"Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A\/J mice","volume":"80","author":"De Albuquerque","year":"2006","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.intimp.2023.110485_b0320","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.intimp.2023.110485_b0325","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiv325","article-title":"Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection","volume":"212","author":"Channappanavar","year":"2015","journal-title":"J Infect Dis"},{"issue":"Pt 8","key":"10.1016\/j.intimp.2023.110485_b0330","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1099\/jmm.0.05320-0","article-title":"Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou","volume":"52","author":"Zhao","year":"2003","journal-title":"PR China, J Med Microbiol."},{"key":"10.1016\/j.intimp.2023.110485_b0335","unstructured":"Public Health England, 2017. https:\/\/www.gov.uk\/government\/publications\/mers-cov-clinical-decision-making-support-for-treatment."},{"key":"10.1016\/j.intimp.2023.110485_b0340","doi-asserted-by":"crossref","unstructured":"Y.P. Chong, J.Y. Song, Y.B. Seo, J.P. Choi, H.S. Shin, T. Rapid Response, Antiviral Treatment Guidelines for Middle East Respiratory Syndrome, Infect Chemother. 47(3) (2015) 212-22, 10.3947\/ic.2015.47.3.212.","DOI":"10.3947\/ic.2015.47.3.212"},{"issue":"5","key":"10.1016\/j.intimp.2023.110485_b0345","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5144\/0256-4947.2014.396","article-title":"Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia","volume":"34","author":"Khalid","year":"2014","journal-title":"Ann. Saudi Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.110485_b0350","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3201\/eid2203.151049","article-title":"Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013","volume":"22","author":"Malik","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2023.110485_b0360","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/jac\/dkv085","article-title":"IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study","volume":"70","author":"Shalhoub","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0365","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4187\/respcare.04325","article-title":"Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS","volume":"61","author":"Khalid","year":"2016","journal-title":"Respir. Care"},{"issue":"11","key":"10.1016\/j.intimp.2023.110485_b0370","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2023.110485_b0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","article-title":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study","volume":"20","author":"Al-Tawfiq","year":"2014","journal-title":"Int. J. Infect. Dis."},{"issue":"04","key":"10.1016\/j.intimp.2023.110485_b0380","article-title":"The Most Effective Therapeutic Regimen for Patients with Severe Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","volume":"03","author":"Al-Qaseer","year":"2015","journal-title":"Infection, Journal of Infectious Diseases & Therapy."},{"key":"10.1016\/j.intimp.2023.110485_b0385","doi-asserted-by":"crossref","unstructured":"Y.M. Arabi, S. Shalhoub, Y. Mandourah, F. Al-Hameed, A. Al-Omari, E. Al Qasim, J. Jose, B. Alraddadi, A. Almotairi, K. Al Khatib, A. Abdulmomen, I. Qushmaq, A.A. Sindi, A. Mady, O. Solaiman, R. Al-Raddadi, K. Maghrabi, A. Ragab, G.A. Al Mekhlafi, H.H. Balkhy, A. Al Harthy, A. Kharaba, J.A. Gramish, A.M. Al-Aithan, A. Al-Dawood, L. Merson, F.G. Hayden, R. Fowler, Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study, Clin Infect Dis. 70(9) (2020) 1837-1844, 10.1093\/cid\/ciz544.","DOI":"10.1093\/cid\/ciz544"},{"key":"10.1016\/j.intimp.2023.110485_b0390","doi-asserted-by":"crossref","unstructured":"M. Al Ghamdi, K.M. Alghamdi, Y. Ghandoora, A. Alzahrani, F. Salah, A. Alsulami, M.F. Bawayan, D. Vaidya, T.M. Perl, G. Sood, Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia, BMC Infect Dis. 16 (2016) 174, 10.1186\/s12879-016-1492-4.","DOI":"10.1186\/s12879-016-1492-4"},{"issue":"3","key":"10.1016\/j.intimp.2023.110485_b0395","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.intimp.2023.110485_b0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tmaid.2019.06.012","article-title":"A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","volume":"30","author":"Momattin","year":"2019","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.110485_b0405","doi-asserted-by":"crossref","unstructured":"Y.M. Arabi, A.Y. Asiri, A.M. Assiri, H.H. Balkhy, A. Al Bshabshe, M. Al Jeraisy, Y. Mandourah, M.H.A. Azzam, A.M. Bin Eshaq, S. Al Johani, S. Al Harbi, H.A.A. Jokhdar, A.M. Deeb, Z.A. Memish, J. Jose, S. Ghazal, S. Al Faraj, G.A. Al Mekhlafi, N.M. Sherbeeni, F.E. Elzein, F. Al-Hameed, A. Al Saedi, N.K. Alharbi, R.A. Fowler, F.G. Hayden, A. Al-Dawood, M. Abdelzaher, W. Bajhmom, B.M. AlMutairi, M.A. Hussein, A. Alothman, G. Saudi Critical Care Trials, Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome, N Engl J Med. 383(17) (2020) 1645-1656, 10.1056\/NEJMoa2015294.","DOI":"10.1056\/NEJMoa2015294"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110485_b0410.1","unstructured":"Y.H. Jin, L. Cai, Z.S. Cheng, H. Cheng, T. Deng, Y.P. Fan, C. Fang, D. Huang, L.Q. Huang, Q. Huang, Y. Han, B. Hu, F. Hu, B.H. Li, Y.R. Li, K. Liang, L.K. Lin, L.S. Luo, J. Ma, L.L. Ma, Z.Y. Peng, Y.B. Pan, Z.Y. Pan, X.Q. Ren, H.M. Sun, Y. Wang, Y.Y. Wang, H. Weng, C.J. Wei, D.F. Wu, J. Xia, Y. Xiong, H.B. Xu, X.M. Yao, Y.F. Yuan, T.S. Ye, X.C. Zhang, Y.W. Zhang, Y.G. Zhang, H.M. Zhang, Y. Zhao, M.J. Zhao, H. Zi, X.T. Zeng, Y.Y. Wang, X.H. Wang, f.t.Z.H.o.W.U.N.C. Management, E.-B.M.C.o.C.I.E. Research Team, M. Promotive Association for, C. Health, A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil Med Res. 7"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110485_b0410.2","unstructured":"(1) (2020) 4, 10.1186\/s40779-020-0233-6."},{"key":"10.1016\/j.intimp.2023.110485_b0415","unstructured":"T.G.O.o.N.H. CommissionOffice, N.T. Administration, Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition), \u611f\u67d3\u6027\u75be\u75c5\u4e0e\u514d\u75ab(\u82f1\u6587). 2(3) (2022) 10."},{"issue":"9","key":"10.1016\/j.intimp.2023.110485_b0420","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2023.110485_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106688","article-title":"Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial","volume":"85","author":"Dastan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0430","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1186\/s12879-020-05425-5","article-title":"Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Infect. Dis."},{"issue":"10238","key":"10.1016\/j.intimp.2023.110485_b0435","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.110485_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110485_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.592543","article-title":"Rationale for COVID-19 Treatment by Nebulized Interferon-beta-1b-Literature Review and Personal Preliminary Experience","volume":"11","author":"Mary","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110485_b0450","doi-asserted-by":"crossref","unstructured":"N. Wang, Y. Zhan, L. Zhu, Z. Hou, F. Liu, P. Song, F. Qiu, X. Wang, X. Zou, D. Wan, X. Qian, S. Wang, Y. Guo, H. Yu, M. Cui, G. Tong, Y. Xu, Z. Zheng, Y. Lu, P. Hong, Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients, Cell Host Microbe. 28(3) (2020) 455-464 e2, 10.1016\/j.chom.2020.07.005.","DOI":"10.1016\/j.chom.2020.07.005"},{"key":"10.1016\/j.intimp.2023.110485_b0455","unstructured":"P.D. Monk, R.J. Marsden, V.J. Tear, J. Brookes, T.N. Batten, M. Mankowski, F.J. Gabbay, D.E. Davies, S.T. Holgate, L.P. Ho, T. Clark, R. Djukanovic, T.M.A. Wilkinson, C.-S.G. Inhaled Interferon Beta, Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Respir Med. 9(2) (2021) 196-206, 10.1016\/S2213-2600(20)30511-7."},{"issue":"5","key":"10.1016\/j.intimp.2023.110485_b0460","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14787210.2022.2004118","article-title":"Clinical efficacy and safety of interferon-beta-containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Chen","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2023.110485_b0465","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00210-021-02061-x","article-title":"Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies","volume":"394","author":"Nakhlband","year":"2021","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110485_b0470","doi-asserted-by":"crossref","unstructured":"A.C. Kalil, A.K. Mehta, T.F. Patterson, N. Erdmann, C.A. Gomez, M.K. Jain, C.R. Wolfe, G.M. Ruiz-Palacios, S. Kline, J. Regalado Pineda, A.F. Luetkemeyer, M.S. Harkins, P.E.H. Jackson, N.M. Iovine, V.F. Tapson, M.D. Oh, J.A. Whitaker, R.A. Mularski, C.I. Paules, D. Ince, J. Takasaki, D.A. Sweeney, U. Sandkovsky, D.L. Wyles, E. Hohmann, K.A. Grimes, R. Grossberg, M. Laguio-Vila, A.A. Lambert, D. Lopez de Castilla, E. Kim, L. Larson, C.R. Wan, J.J. Traenkner, P.O. Ponce, J.E. Patterson, P.A. Goepfert, T.A. Sofarelli, S. Mocherla, E.R. Ko, A. Ponce de Leon, S.B. Doernberg, R.L. Atmar, R.C. Maves, F. Dangond, J. Ferreira, M. Green, M. Makowski, T. Bonnett, T. Beresnev, V. Ghazaryan, W. Dempsey, S.U. Nayak, L. Dodd, K.M. Tomashek, J.H. Beigel, A.-s.g. members, Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial, Lancet Respir Med. 9(12) (2021) 1365-1376, 10.1016\/S2213-2600(21)00384-2.","DOI":"10.1056\/NEJMoa2031994"},{"key":"10.1016\/j.intimp.2023.110485_b0475","unstructured":"W.H.O.S.T. Consortium, H. Pan, R. Peto, A.M. Henao-Restrepo, M.P. Preziosi, V. Sathiyamoorthy, Q. Abdool Karim, M.M. Alejandria, C. Hernandez Garcia, M.P. Kieny, R. Malekzadeh, S. Murthy, K.S. Reddy, M. Roses Periago, P. Abi Hanna, F. Ader, A.M. Al-Bader, A. Alhasawi, E. Allum, A. Alotaibi, C.A. Alvarez-Moreno, S. Appadoo, A. Asiri, P. Aukrust, A. Barratt-Due, S. Bellani, M. Branca, H.B.C. Cappel-Porter, N. Cerrato, T.S. Chow, N. Como, J. Eustace, P.J. Garcia, S. Godbole, E. Gotuzzo, L. Griskevicius, R. Hamra, M. Hassan, M. Hassany, D. Hutton, I. Irmansyah, L. Jancoriene, J. Kirwan, S. Kumar, P. Lennon, G. Lopardo, P. Lydon, N. Magrini, T. Maguire, S. Manevska, O. Manuel, S. McGinty, M.T. Medina, M.L. Mesa Rubio, M.C. Miranda-Montoya, J. Nel, E.P. Nunes, M. Perola, A. Portoles, M.R. Rasmin, A. Raza, H. Rees, P.P.S. Reges, C.A. Rogers, K. Salami, M.I. Salvadori, N. Sinani, J.A.C. Sterne, M. Stevanovikj, E. Tacconelli, K.A.O. Tikkinen, S. Trelle, H. Zaid, J.A. Rottingen, S. Swaminathan, Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results, N Engl J Med. 384(6) (2021) 497-511, 10.1056\/NEJMoa2023184."},{"key":"10.1016\/j.intimp.2023.110485_b0480","doi-asserted-by":"crossref","unstructured":"F. Ader, N. Peiffer-Smadja, J. Poissy, M. Bouscambert-Duchamp, D. Belhadi, A. Diallo, C. Delmas, J. Saillard, A. Dechanet, N. Mercier, A. Dupont, T. Alfaiate, F.X. Lescure, F. Raffi, F. Goehringer, A. Kimmoun, S. Jaureguiberry, J. Reignier, S. Nseir, F. Danion, R. Clere-Jehl, K. Bouiller, J.C. Navellou, V. Tolsma, A. Cabie, C. Dubost, J. Courjon, S. Leroy, J. Mootien, R. Gaci, B. Mourvillier, E. Faure, V. Pourcher, S. Gallien, O. Launay, K. Lacombe, J.P. Lanoix, A. Makinson, G. Martin-Blondel, L. Bouadma, E. Botelho-Nevers, A. Gagneux-Brunon, O. Epaulard, L. Piroth, F. Wallet, J.C. Richard, J. Reuter, T. Staub, B. Lina, M. Noret, C. Andrejak, M.P. Le, G. Peytavin, M. Hites, D. Costagliola, Y. Yazdanpanah, C. Burdet, F. Mentre, g. DisCoVeRy study, An open-label randomized controlled trial of the effect of lopinavir\/ritonavir, lopinavir\/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19, Clin Microbiol Infect. 27(12) (2021) 1826-1837, 10.1016\/j.cmi.2021.05.020.","DOI":"10.1101\/2022.02.16.22271064"},{"key":"10.1016\/j.intimp.2023.110485_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.746602","article-title":"The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors","volume":"12","author":"Lui","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"10.1016\/j.intimp.2023.110485_b0490","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.intimp.2023.110485_b0495","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMe2034294","article-title":"Simple Trial Leading to Complex Questions","volume":"384","author":"Harrington","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2023.110485_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810968","article-title":"Correlation between Type I Interferon Associated Factors and COVID-19 Severity","volume":"23","author":"Bencze","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.110485_b0505","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.intimp.2023.110485_b0510","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","article-title":"Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial","volume":"11","author":"Alavi Darazam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110485_b0515","doi-asserted-by":"crossref","unstructured":"E. Andreakos, S. Tsiodras, COVID-19: lambda interferon against viral load and hyperinflammation, EMBO Mol Med. 12(6) (2020) e12465, 10.15252\/emmm.202012465.","DOI":"10.15252\/emmm.202012465"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:44Z","timestamp":1761588284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":104,"alternative-id":["S1567576923008081"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110485","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110485"}}